Topics

NICE rejects Roche's immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

05:17 EDT 3 Oct 2019 | Pharmafile

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and Wales for the treatment of unresectable, metastatic triple A breast cancer.

The decision puts the UK watchdog at odds with the FDA and EMA, who both saw fit to approve the drug – their first approved therapy for triple A breast cancer patients. Tecentriq works by blocking PD-L1, and is the first immunotherapy to specifically target tumours which express the protein by 1% or more.

read more

Original Article: NICE rejects Roche's immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

NEXT ARTICLE

More From BioPortfolio on "NICE rejects Roche's immunotherapy Tecentriq in unresectable metastatic triple A breast cancer"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...